TrialThe Lancet. Oncology2019
Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial.
David Cella et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
139 papers cite itlatest 60 shown
this paperpooled ittrialcites it